Author(s)

Robin Rosenblate, MD

Instructor in the Department of Psychiatry at Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

Disclosures

Disclosure: Robin L. Rosenblate, MD, has disclosed grant and research support from Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Cephalon, Inc., Cyberonics, Inc., Glaxo-Wellcome, MIICRO, Inc., Organon, Inc., Otsuka America Pharmaceutical Inc., Parke-Davis Pharmaceuticals, Pharmacia & Upjohn, and Sanofi Research. Content of this activity does include off-label discussion of the following: topiramate, Ginkgo biloba extract, bethenechol, neostigmine, buspirone, bupropin, mirtazapine, nefazodone, granisetron and yohimbine.

John Zajecka, MD

Associate Professor in the Department of Psychiatry at Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

Disclosures

Disclosure: John M. Zajecka, MD, has disclosed that he receives grant and research support from Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Cephalon, Cyberonics, Inc., Glaxo Wellcome, MIICRO, Inc., Organon, Inc., Otsuka America Pharmaceutical Inc., Parke-Davis Pharmaceuticals, Pfizer, Inc., Pharmacia & Upjohn, and Sanofi Research. He is a consultant to Abbott Laboratories, Bristol-Myers Squibb, and Eli Lilly and Company. He is also a member of speakers' bureaus for Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer/Roerig, SmithKline Beecham, Upjohn Company, and Wyeth-Ayerst Laboratories. Content of this activity does include off-label discussion of the following: topiramate, Ginkgo biloba extract, bethenechol, neostigmine, buspirone, bupropin, mirtazapine, nefazodone, granisetron and yohimbine.

Editor(s)

Robert Kennedy

Program director/site editor of Medscape Psychiatry & Mental Health

CME/CE

Treatment Resistant Depression: A Guide for Effective Psychopharmacologists

Authors: Authors: Robin Rosenblate, MD, John Zajecka, MD
THIS ACTIVITY HAS EXPIRED FOR CREDIT

Start Activity

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians, pharmacists, and other mental health professionals.

The goal of this activity is to provide current treatment protocols and clinical strategies for the treatment and management of resistant depression.

On completion of this continuing medical education offering, participants will be able to:

Review the issues of compliance, side effects and other issues that can interfere with the proper treatment of depressive disorders.
Elaborate on the various interventions for resistant depressive disorders.
Identify the important do's and don'ts in the treatment for depressive disorders.

Author(s)

Robin Rosenblate, MD

Instructor in the Department of Psychiatry at Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

Disclosures

Disclosure: Robin L. Rosenblate, MD, has disclosed grant and research support from Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Cephalon, Inc., Cyberonics, Inc., Glaxo-Wellcome, MIICRO, Inc., Organon, Inc., Otsuka America Pharmaceutical Inc., Parke-Davis Pharmaceuticals, Pharmacia & Upjohn, and Sanofi Research. Content of this activity does include off-label discussion of the following: topiramate, Ginkgo biloba extract, bethenechol, neostigmine, buspirone, bupropin, mirtazapine, nefazodone, granisetron and yohimbine.

John Zajecka, MD

Associate Professor in the Department of Psychiatry at Rush-Presbyterian-St. Luke's Medical Center Chicago, Illinois

Disclosures

Disclosure: John M. Zajecka, MD, has disclosed that he receives grant and research support from Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Cephalon, Cyberonics, Inc., Glaxo Wellcome, MIICRO, Inc., Organon, Inc., Otsuka America Pharmaceutical Inc., Parke-Davis Pharmaceuticals, Pfizer, Inc., Pharmacia & Upjohn, and Sanofi Research. He is a consultant to Abbott Laboratories, Bristol-Myers Squibb, and Eli Lilly and Company. He is also a member of speakers' bureaus for Abbott Laboratories, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer/Roerig, SmithKline Beecham, Upjohn Company, and Wyeth-Ayerst Laboratories. Content of this activity does include off-label discussion of the following: topiramate, Ginkgo biloba extract, bethenechol, neostigmine, buspirone, bupropin, mirtazapine, nefazodone, granisetron and yohimbine.

Editor(s)

Robert Kennedy

Program director/site editor of Medscape Psychiatry & Mental Health

Accreditation Statements

For Physicians

Medical Education Collaborative, a nonprofit education organization, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medical Education Collaborative designates this educational activity for a maximum of 1 hour in Category 1 credit towards the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Contact This Provider

For Pharmacists

Medical Education Collaborative, Inc. has assigned 1 contact hour (0.10 CEUs) of continuing pharmaceutical education credit. ACPE provider number: 815-999-00-089-H04. Certificate is defined as a record of participation.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page.

Follow these steps to earn CME/CE credit:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. Medscape encourages you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 5 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

The credit that you receive is based on your user profile.

processing....

References

Faculty and Disclosures

Author(s)

Robin Rosenblate, MD

John Zajecka, MD

Editor(s)

Robert Kennedy

CME/CE

Treatment Resistant Depression: A Guide for Effective Psychopharmacologists

Target Audience and Goal Statement

Author(s)

Robin Rosenblate, MD

John Zajecka, MD

Editor(s)

Robert Kennedy

Accreditation Statements

For Physicians

For Pharmacists

Instructions for Participation and Credit

Treatment Resistant Depression: A Guide for Effective Psychopharmacologists